Enfortumab vedotin (EV) is the first drug in this new class to be approved by the EMA at for the treatment of patients and patients with metastatic urothelial carcinoma. Given the extremely ...

Enter Seattle Genetics and Astellas, who are jointly developing enfortumab vedotin, an antibody-drug conjugate intended as an option for patients whose disease has progressed despite treatment ...

So in the metastatic setting, as of about a year ago, the big change was the approval of enfortumab vedotin and pembrolizumab combination for patients with metastatic disease who are treatment ...